{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:27:03Z","timestamp":1791174423612,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04795-4","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T08:15:13Z","timestamp":1751876113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk factors and prediction models for cardiotoxicity induced by anthracyclines in malignant chemotherapy"],"prefix":"10.1007","volume":"95","author":[{"given":"Pengxiang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongchao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meina","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"4795_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-016-6711-0","author":"JV Mcgowan","year":"2017","unstructured":"Mcgowan JV, Chung R, Maulik A et al (2017) Anthracycline Chemotherapy and Cardiotoxicity[J]. Cardiovascular Drugs and Therapy. https:\/\/doi.org\/10.1007\/s10557-016-6711-0","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"4795_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22136923","author":"Y Sun","year":"2021","unstructured":"Sun Y, Liu Y, Ma X et al (2021) The Influence of Cell Cycle Regulation on Chemotherapy[J]. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22136923","journal-title":"Int J Mol Sci"},{"issue":"2024\u201312\u201322","key":"4795_CR3","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.3390\/molecules27072122","volume":"27","author":"W Xing","year":"2022","unstructured":"Xing W, Wen C, Wang D et al (2022) Cardiorenal protective effect of Costunolide against Doxorubicin-Induced toxicity in rats by modulating oxidative stress, inflammation and Apoptosis[J]. Molecules 27(2024\u201312\u201322):2122","journal-title":"Molecules"},{"issue":"1","key":"4795_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/10428194.2020.1817442","volume":"62","author":"F Nakamura","year":"2020","unstructured":"Nakamura F, Arai H, Tokita K et al (2020) PECAM is an effective and safe Anthracycline-Containing Third-Line regimen for patients with relapsed or refractory Non-Hodgkin Lymphoma[J]. Leuk Lymphoma\/Leukemia Lymphoma 62(1):239\u2013242","journal-title":"Leuk Lymphoma\/Leukemia Lymphoma"},{"issue":"2024\u201312\u201322","key":"4795_CR5","first-page":"10","volume":"10","author":"H Jin","year":"2023","unstructured":"Jin H, Xu J, Sui Z et al (2023) Risk factors from Framingham risk score for anthracyclines cardiotoxicity in breast cancer: A systematic review and Meta-Analysis.[J]. Front Cardiovasc Med 10(2024\u201312\u201322):10","journal-title":"Front Cardiovasc Med"},{"key":"4795_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031247","author":"VA Timoshnikov","year":"2022","unstructured":"Timoshnikov VA, Selyutina OY, Polyakov NE et al (2022) Mechanistic Insights of Chelator Complexes with Essential Transition Metals: Antioxidant\/Pro-Oxidant Activity and Applications in Medicine[J]. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23031247","journal-title":"Int J Mol Sci"},{"key":"4795_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/biom13040683","author":"ES Turilli-Ghisolfi","year":"2023","unstructured":"Turilli-Ghisolfi ES, Lualdi M, Fasano M (2023) Ligand-Based Regulation of Dynamics and Reactivity of Hemoproteins[J]. Biomolecules. https:\/\/doi.org\/10.3390\/biom13040683","journal-title":"Biomolecules"},{"issue":"2024\u201312\u201322","key":"4795_CR8","doi-asserted-by":"publisher","first-page":"912329","DOI":"10.3389\/fcvm.2022.912329","volume":"9","author":"W Huang","year":"2022","unstructured":"Huang W, Xu R, Zhou B et al (2022) Clinical manifestations, monitoring, and prognosis: A review of cardiotoxicity after antitumor Strategy[J]. Front Cardiovasc Med 9(2024\u201312\u201322):912329","journal-title":"Front Cardiovasc Med"},{"key":"4795_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030627","author":"WMC van den Boogaard","year":"2022","unstructured":"van den Boogaard WMC, Komninos DSJ, Vermeij WP (2022) Chemotherapy Side-Effects: Not All DNA Damage is Equal [J]. Cancers. https:\/\/doi.org\/10.3390\/cancers14030627","journal-title":"Cancers"},{"issue":"13","key":"4795_CR10","doi-asserted-by":"publisher","first-page":"7477","DOI":"10.3390\/ijms25137477","volume":"25","author":"R Vitale","year":"2024","unstructured":"Vitale R, Marzocco S, Popolo A (2024) Role of Oxidative Stress and Inflammation in Doxorubicin-Induced Cardiotoxicity: A Brief Account[J]. Int J Mol Sci 25(13):7477","journal-title":"Int J Mol Sci"},{"issue":"2025\u20131\u201319","key":"4795_CR11","doi-asserted-by":"publisher","first-page":"811406","DOI":"10.3389\/fphar.2022.811406","volume":"13","author":"J Huang","year":"2022","unstructured":"Huang J, Wu R, Chen L et al (2022) Understanding anthracycline cardiotoxicity from mitochondrial Aspect[J]. Front Pharmacol 13(2025\u20131\u201319):811406","journal-title":"Front Pharmacol"},{"issue":"2025\u20131\u201319","key":"4795_CR12","doi-asserted-by":"publisher","first-page":"1406247","DOI":"10.3389\/fphar.2024.1406247","volume":"15","author":"S Xie","year":"2024","unstructured":"Xie S, Sun Y, Zhao X et al (2024) An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity[J]. Front Pharmacol 15(2025\u20131\u201319):1406247","journal-title":"Front Pharmacol"},{"key":"4795_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.biopha.2018.07.037","volume":"109","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Yang J, Zhang H (2019) Carvedilol (CAR) combined with carnosic acid (CAA) attenuates doxorubicin-induced cardiotoxicity by suppressing excessive oxidative stress, inflammation, apoptosis and autophagy[J]. Biomed Pharmacother 109:71\u201383","journal-title":"Biomed Pharmacother"},{"key":"4795_CR14","doi-asserted-by":"crossref","unstructured":"Tang WW, Biomedical Literature (2018) Faculty Opinions Recommendation of 2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed under the Auspices of the ESC Committee for Practice Guidelines: the Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC).[J]. Faculty Opinions\u2013 Post-Publication Peer Review of the. 2025(2025-1-19): Abbreviations and acronyms2770P-Abbreviations and acronyms27701P","DOI":"10.3410\/f.726697846.793550710"},{"key":"4795_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2022.03.010","author":"Y Kim","year":"2022","unstructured":"Kim Y, Seidman JG, Seidman CE (2022) Genetics of Cancer Therapy-Associated Cardiotoxicity[J]. J Mol Cell Cardiol. https:\/\/doi.org\/10.1016\/j.yjmcc.2022.03.010","journal-title":"J Mol Cell Cardiol"},{"issue":"2025\u20131\u201319","key":"4795_CR16","first-page":"40","volume":"11","author":"S Balaji","year":"2023","unstructured":"Balaji S, Antony AK, Tonchev H et al (2023) Racial disparity in Anthracycline-induced cardiotoxicity in breast Cancer Patients[J]. BIOMEDICINES 11(2025\u20131\u201319):40","journal-title":"BIOMEDICINES"},{"key":"4795_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2023.101332","author":"C Belger","year":"2024","unstructured":"Belger C, Abrahams C, Imamdin A et al (2024) Doxorubicin-induced Cardiotoxicity and Risk Factors[J]. Int J Cardiol Heart Vasc. https:\/\/doi.org\/10.1016\/j.ijcha.2023.101332","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"2025\u20131\u201319","key":"4795_CR18","doi-asserted-by":"publisher","first-page":"753313","DOI":"10.3389\/fcvm.2021.753313","volume":"8","author":"H Xiao","year":"2021","unstructured":"Xiao H, Wang X, Li S et al (2021) Advances in biomarkers for detecting early Cancer Treatment-Related cardiac Dysfunction[J]. Front Cardiovasc Med 8(2025\u20131\u201319):753313","journal-title":"Front Cardiovasc Med"},{"key":"4795_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.029574","author":"G Murtagh","year":"2023","unstructured":"Murtagh G, Januzzi JL, Scherrer-Crosbie M et al (2023) Circulating Cardiovascular Biomarkers in Cancer Therapeutics-Related Cardiotoxicity: Review of Critical Challenges, Solutions, and Future Directions[J]. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.123.029574","journal-title":"J Am Heart Assoc"},{"key":"4795_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/biom14020199","author":"U Attanasio","year":"2024","unstructured":"Attanasio U, Di Sarro E, Tricarico L et al (2024) Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond[J]. Biomolecules. https:\/\/doi.org\/10.3390\/biom14020199","journal-title":"Biomolecules"},{"key":"4795_CR21","first-page":"1525638977","volume":"11","author":"CR Manrique","year":"2017","unstructured":"Manrique CR, Park M, Tiwari N et al (2017) Diagnostic strategies for early recognition of Cancer Therapeutics\u2013Related cardiac Dysfunction[J]. Clin Med Insights: Cardiol 11:1525638977","journal-title":"Clin Med Insights: Cardiol"},{"issue":"1","key":"4795_CR22","doi-asserted-by":"publisher","first-page":"101033","DOI":"10.1016\/j.jocmr.2024.101033","volume":"26","author":"K Nakata","year":"2024","unstructured":"Nakata K, Kucukseymen S, Cai X et al (2024) Cardiovascular magnetic resonance characterization of myocardial tissue injury in a miniature swine model of cancer therapy-related cardiovascular toxicity[J]. J Cardiovasc Magn Reson 26(1):101033","journal-title":"J Cardiovasc Magn Reson"},{"issue":"23","key":"4795_CR23","doi-asserted-by":"publisher","first-page":"e19628","DOI":"10.1161\/JAHA.120.019628","volume":"9","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Hou Y, Hussain M et al (2020) Machine Learning-Based risk assessment for Cancer Therapy-Related cardiac dysfunction in 4300 longitudinal oncology Patients[J]. J Am Heart Assoc 9(23):e19628","journal-title":"J Am Heart Assoc"},{"key":"4795_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12911-024-02603-2","volume":"24","author":"C Cheng","year":"2024","unstructured":"Cheng C, Lee B, Nfor ON et al (2024) Using machine learning-based algorithms to construct cardiovascular risk prediction models for Taiwanese adults based on traditional and novel risk factors[J]. BMC Med Inf Decis Mak 24:199","journal-title":"BMC Med Inf Decis Mak"},{"issue":"1","key":"4795_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3348\/kjr.2018.0231","volume":"20","author":"J Koh","year":"2019","unstructured":"Koh J, Kim MJ (2019) Introduction of a new staging system of breast Cancer for radiologists: an emphasis on the prognostic Stage[J]. Korean J Radiol 20(1):69","journal-title":"Korean J Radiol"},{"key":"4795_CR26","doi-asserted-by":"publisher","first-page":"e1002989","DOI":"10.1371\/journal.pmed.1002989","volume":"16","author":"EG Kabore","year":"2019","unstructured":"Kabore EG, Guenancia C, Vaz-Luis I et al (2019) Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort Study[J]. PLoS Med 16:e1002989","journal-title":"PLoS Med"},{"key":"4795_CR27","doi-asserted-by":"publisher","unstructured":"Gupta A, Guyomard V, Zaman MJS et al (2010) Systematic review on evidence of the effectiveness of cholesterol-lowering drugs[J]. Adv Therapy 27(6):348-364 https:\/\/doi.org\/10.1007\/s12325-010-0033-6","DOI":"10.1007\/s12325-010-0033-6"},{"issue":"4","key":"4795_CR28","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2147\/ciia.2006.1.4.433","volume":"1","author":"WS Aronow","year":"2006","unstructured":"Aronow WS (2006) Management of hyperlipidemia with Statins in the older patient[J]. Clin Interv Aging 1(4):433\u2013438","journal-title":"Clin Interv Aging"},{"key":"4795_CR29","doi-asserted-by":"publisher","first-page":"e196763","DOI":"10.1371\/journal.pone.0196763","volume":"13","author":"P Veronese","year":"2018","unstructured":"Veronese P, Hachul DT, Scanavacca MI et al (2018) Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast Cancer.[J]. PLoS ONE 13:e196763","journal-title":"PLoS ONE"},{"key":"4795_CR30","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.orcp.2016.09.005","volume":"11","author":"S Waheed","year":"2016","unstructured":"Waheed S, Dawn B, Gupta K (2016) Association of corrected QT interval with body mass index, and the impact of this association on mortality: results from the third National health and nutrition examination Survey.[J]. Obes Res Clin Pract 11:426\u2013434","journal-title":"Obes Res Clin Pract"},{"issue":"2","key":"4795_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1600-0609.1999.tb01734.x","volume":"62","author":"T Nousiainen","year":"1999","unstructured":"Nousiainen T, Jantunen E, Vanninen E et al (1999) Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin\u2019s lymphoma[J]. Eur J Haematol 62(2):135\u2013141","journal-title":"Eur J Haematol"},{"issue":"3","key":"4795_CR32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1046\/j.1365-2796.2002.00951.x","volume":"251","author":"T Nousiainen","year":"2002","unstructured":"Nousiainen T, Vanninen E, Jantunen E et al (2002) Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction[J]. J Intern Med 251(3):228\u2013234","journal-title":"J Intern Med"},{"key":"4795_CR33","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1001\/archinte.164.18.1978","volume":"164","author":"JA Doust","year":"2004","unstructured":"Doust JA, Glasziou PP, Pietrzak E et al (2004) A systematic review of the diagnostic accuracy of natriuretic peptides for heart Failure[J]. Arch Intern Med 164:1978\u20131984","journal-title":"Arch Intern Med"},{"issue":"5","key":"4795_CR34","doi-asserted-by":"publisher","first-page":"e96736","DOI":"10.1371\/journal.pone.0096736","volume":"9","author":"D Skovgaard","year":"2014","unstructured":"Skovgaard D, Hasbak P, Kjaer A (2014) BNP predicts Chemotherapy-Related cardiotoxicity and death: comparison with gated equilibrium radionuclide Ventriculography[J]. PLoS ONE 9(5):e96736","journal-title":"PLoS ONE"},{"key":"4795_CR35","doi-asserted-by":"crossref","unstructured":"Michel L, Rassaf T, Totzeck M (2018) Biomarkers for the detection of apparent and subclinical Cancer Therapy-Related Cardiotoxicity[J]. Journal of Thoracic Disease, p 10","DOI":"10.21037\/jtd.2018.08.15"},{"key":"4795_CR36","doi-asserted-by":"publisher","first-page":"8290","DOI":"10.1074\/jbc.M308033200","volume":"279","author":"CC Lim","year":"2004","unstructured":"Lim CC, Zuppinger C, Guo XX et al (2004) Anthracyclines induce Calpain-dependent Titin proteolysis and necrosis in Cardiomyocytes*[J]. J Biol Chem 279:8290\u20138299","journal-title":"J Biol Chem"},{"key":"4795_CR37","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","volume":"18","author":"S Zhang","year":"2012","unstructured":"Zhang S, Liu X, Bawa-Khalfe T et al (2012) Identification of the molecular basis of Doxorubicin-Induced Cardiotoxicity.[J]. Nat Med 18:1639\u20131642","journal-title":"Nat Med"},{"key":"4795_CR38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.pcad.2010.06.007","volume":"53","author":"DB Sawyer","year":"2010","unstructured":"Sawyer DB, Peng X, Chen B et al (2010) Mechanisms of anthracycline cardiac injury: can we identify strategies for Cardioprotection?[J]. Prog Cardiovasc Dis 53:105\u2013113","journal-title":"Prog Cardiovasc Dis"},{"key":"4795_CR39","first-page":"4592","volume":"62","author":"AC Childs","year":"2002","unstructured":"Childs AC, Phaneuf SL, Dirks AJ et al (2002) Doxorubicin Treatment in Vivo Causes Cytochrome C Release and Cardiomyocyte Apoptosis, As Well As Increased Mitochondrial Efficiency, Superoxide Dismutase Activity, and Bcl-2:Bax Ratio.[J]. PubMed. Cancer Res 62:4592\u20134598","journal-title":"Cancer Res"},{"key":"4795_CR40","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2004.08.066","volume":"44","author":"LP Grazette","year":"2004","unstructured":"Grazette LP, Boecker W, Matsui T et al (2004) Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for Herceptin-Induced Cardiomyopathy.[J]. J Am Coll Cardiol 44:2231\u20132238","journal-title":"J Am Coll Cardiol"},{"key":"4795_CR41","doi-asserted-by":"crossref","unstructured":"Sandoo A, Kitas GD, Carmichael AR (2015) Breast Cancer therapy and cardiovascular risk: focus on Trastuzumab[J]. Vascular Health and Risk Management, p 11","DOI":"10.2147\/VHRM.S69641"},{"key":"4795_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30570-9","author":"MS van Ramshorst","year":"2018","unstructured":"van Ramshorst MS, van der Voort A, van Werkhoven ED et al (2018) Neoadjuvant Chemotherapy with or Without Anthracyclines in the Presence of Dual HER2 Blockade for HER2-positive Breast Cancer (TRAIN-2): a Multicentre, Open-Label, Randomised, Phase 3 Trial[J]. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(18)30570-9","journal-title":"Lancet Oncol"},{"issue":"14","key":"4795_CR43","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1056\/NEJMe2411493","volume":"391","author":"EJ Rubin","year":"2024","unstructured":"Rubin EJ, Yeku OO, Morrissey S (2024) NEJM at ESMO - Pembrolizumab in HER2\u2009+\u2009Gastric Cancer[J]. N Engl J Med 391(14):e30","journal-title":"N Engl J Med"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04795-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04795-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04795-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T08:15:16Z","timestamp":1751876116000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04795-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4795"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04795-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the ethics committee of Shijiazhuang People\u2019s Hospital, and all patients had given the signed informed consent to participate.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval\u00a0and Consent to participate"}}],"article-number":"73"}}